Swedish Orphan International’s business concept is to develop and make available orphan drugs – drugs designated for the treatment of rare, life-threatening or chronically debilitating diseases - and products for which there exists an unmet medical need. Swedish Orphan International was founded in 1988 and is a pioneer within the area of orphan drugs. Swedish Orphan International has for several years been one of Sweden’s fastest growing companies, and now has subsidiaries covering all of Europe.
The deal is made by Palettes partner Omnilog, september 2009